Surgical Treatment of High Stage Endometrial Cancer: Current Perspectives

Overview

Journal Updates Surg

Specialty General Surgery

Date 2016 Jan 31

PMID 26826083

Citations 21

Authors

Salvatore Giovanni Vitale

Gaetano Valenti

Ferdinando Antonio Gulino

Pietro Cignini

Antonio Biondi

Affiliations

Soon will be listed here.

Abstract

Endometrial cancer is now the most common gynecologic malignancy. We investigate on new scientific evidences in endometrial cancer, particularly underlined updates in advanced endometrial cancer. Early stage endometrial cancer is the most frequent presentation; however, advanced endometrial cancer that occurs in 3-13 % of cases has bad prognosis. There are two types of endometrial cancer different in molecular pattern, therapeutic strategy and prognosis. Type I endometrial cancers develop in an environment of unopposed estrogen and often arise out of endometrial hyperplasia, characterized by mutations in the PTEN gene, K-ras, and microsatellite instability inception. Type II cancer is not an estrogen-related cancer, occurs predominantly in postmenopausal women, shows typical mutations in p53 and HER2/neu and has a poor prognosis. Preoperative characterization of the type's disease is an essential step for a right diagnosis and treatment. All patients should undergo to surgical staging, except those who are inoperable, according to FIGO recommendation. Surgical debulking, neoadjuvant chemotherapy and interval debulking can be strategy options.

Citing Articles

Survival benefit of cytoreductive surgery in patients with primary stage IV endometrial cancer: a systematic review & meta-analysis.

Pham E, Horeweg N, van der Marel J, Nooij L BJC Rep. 2024; 2(1):76.

PMID: 39516418 PMC: 11523991. DOI: 10.1038/s44276-024-00084-4.

is a novel prognostic biomarker in endometrial cancer and is associated with immune infiltration.

Liang C, Chen Y, Chen S, She J, Shi Q, Wang P Transl Cancer Res. 2024; 12(12):3641-3652.

PMID: 38192989 PMC: 10774036. DOI: 10.21037/tcr-23-697.

JGOG2046: a feasibility study of neoadjuvant chemotherapy followed by debulking surgery for clinically diagnosed FIGO stage IVb endometrial cancer.

Nakanishi T, Saito T, Aoki D, Watanabe Y, Ushijima K, Takano M Int J Clin Oncol. 2023; 28(3):436-444.

PMID: 36729215 DOI: 10.1007/s10147-022-02284-9.

Effects of RFRP‑3 on an ovariectomized estrogen‑primed rat model and HEC‑1A human endometrial carcinoma cells.

Zhao X, Si L, Niu L, Wei M, Wang F, Liu X Exp Ther Med. 2023; 25(2):76.

PMID: 36684658 PMC: 9842939. DOI: 10.3892/etm.2022.11775.

Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series.

Grube M, Reijnen C, Lucas P, Kommoss F, Kommoss F, Brucker S J Cancer Res Clin Oncol. 2022; 149(7):3361-3369.

PMID: 35939115 PMC: 10314833. DOI: 10.1007/s00432-022-04218-4.

References

Lambrou N, Gomez-Marin O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z . Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol. 2004; 93(3):653-8. DOI: 10.1016/j.ygyno.2004.03.015. View

Whitney C, Brunetto V, Zaino R, Lentz S, Sorosky J, Armstrong D . Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(1):4-9. DOI: 10.1016/j.ygyno.2003.09.018. View

Ivanova T, Krikunova L, Ryabchenko N, Mkrtchyan L, Khorokhorina V, Salnikova L . Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma. Oxid Med Cell Longev. 2015; 2015:593658. PMC: 4337044. DOI: 10.1155/2015/593658. View

Bristow R, Zerbe M, Rosenshein N, Grumbine F, Montz F . Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000; 78(2):85-91. DOI: 10.1006/gyno.2000.5843. View

Ueda S, Kapp D, Cheung M, Shin J, Osann K, Husain A . Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008; 198(2):218.e1-6. DOI: 10.1016/j.ajog.2007.08.075. View

Mariani A, Dowdy S, Cliby W, Gostout B, Jones M, Wilson T . Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008; 109(1):11-8. PMC: 3667391. DOI: 10.1016/j.ygyno.2008.01.023. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

Di Cello A, Rania E, Zuccala V, Venturella R, Mocciaro R, Zullo F . Failure to recognize preoperatively high-risk endometrial carcinoma is associated with a poor outcome. Eur J Obstet Gynecol Reprod Biol. 2015; 194:153-60. DOI: 10.1016/j.ejogrb.2015.09.004. View

Vincent H, Taylor A . Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2005; 30(3):400-18. DOI: 10.1038/sj.ijo.0803177. View

10.

Einstein M, Rice L . Current surgical management of endometrial cancer. Hematol Oncol Clin North Am. 2012; 26(1):79-91. DOI: 10.1016/j.hoc.2011.10.005. View

11.

Chi D, Welshinger M, Venkatraman E, Barakat R . The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol. 1997; 67(1):56-60. DOI: 10.1006/gyno.1997.4838. View

12.

Sutton G, Axelrod J, Bundy B, Roy T, Homesley H, Malfetano J . Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2005; 97(3):755-63. DOI: 10.1016/j.ygyno.2005.03.011. View

13.

Ferguson S, Soslow R, Amsterdam A, Barakat R . Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol. 2005; 101(2):322-6. DOI: 10.1016/j.ygyno.2005.10.026. View

14.

Westin S, Broaddus R . Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2011; 13(1):1-13. PMC: 3335980. DOI: 10.4161/cbt.13.1.18438. View

15.

Ayhan A, Taskiran C, Celik C, Yuce K, Kucukali T . The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int J Gynecol Cancer. 2002; 12(5):448-53. DOI: 10.1046/j.1525-1438.2002.t01-1-01133.x. View

16.

Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M . Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014; 120(19):2986-95. DOI: 10.1002/cncr.28853. View

17.

Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

18.

Schmandt R, Iglesias D, Co N, Lu K . Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011; 205(6):518-25. PMC: 4264838. DOI: 10.1016/j.ajog.2011.05.042. View

19.

Renehan A, Tyson M, Egger M, Heller R, Zwahlen M . Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X. View

20.

Pliskow S, Penalver M, AVERETTE H . Stage III and stage IV endometrial carcinoma: a review of 41 cases. Gynecol Oncol. 1990; 38(2):210-5. DOI: 10.1016/0090-8258(90)90043-k. View